An unusual strategy lets you virtually "recreate" gains off the biggest companies you thought had come and gone. CLICK HERE to see how it works.
Nucor (NYSE: NUE) & The Golden Dividend Ratio
There has been a lot of talk about value traps recently. With dozens of companies slashing or halting their dividends, many income investors have seen a “double whammy” of lower portfolio values and lower revenues.
And while it’s real easy to find losers, the dividend winners are much harder to find.
Seven that Money Magazine looked at include 3M (NYSE: MMM), Johnson & Johnson (NYSE: JNJ), PepsiCo (NYSE: PEP), Emerson Electric (NYSE: EMR), Nucor (NYSE: NUE), Dover (NYSE: DOV) and Clorox (NYSE: CLX).
These dividend stocks all have something interesting in common – in addition to the fact they’re each raised dividends for at least 25 years. It’s their yield.
The yields on these companies range from 3.1% to 3.8%. Consider it the “golden ratio” of dividends. It laymen’s terms, it’s the amount a company can comfortably pay out while still keeping enough for reinvestment and growth.
Looking at the growth rate of their stocks, the worst performer, 3M, has only returned a 447.1% return over the last 25 years. It’s annualized return of 17.88% still beats the S&P’s (.INX) 16.36%. The best performer from that group, Nucor, has an annualized return of 100.25%.
It should give investors pause about investing only in the highest yielding stocks.
Companies mentioned in this article: MMM, JNJ, PEP, EMR, NUE, DOV and CLX.
- Dividend-Paying Stocks: 5 Pharmaceutical “Cash Machines”
- Choosing Dividend Stocks: Six Steps For Finding These Safe, High-Yield Investments
- Investing In Dividend-Paying Stocks: A “Strong Buy” Since 1935
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
Investment U RSS Feed